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Pathophysiology on Atherogenesis in SLE
In the U.S., approximately 5-20 
people per 100,000 are affected with the 
complex autoimmune disorder called 
Systemic Lupus Erythematosus (SLE). 
SLE affects predominately more females 
than males (9:1female to male), with a 
higher incidence in African American 
women. (Barbehaiya, Costenbader, 
Parks, & Santos, 2017). SLE is a 
debilitating condition that has 
multisystem involvement which affects 
the skin, renal, musculoskeletal, and 
cardiac systems. “SLE is caused by 
interactions between susceptible genes 
and environmental factors, which can 
include ultraviolet light, infections, and 
viruses, resulting in an irreversible loss 
of immunologic self-tolerance” 
(Garyfallos, Goulielmos, Niewold, & 
...Zervou, 2018, p. 59). 
Cardiovascular disease is a leading 
cause of mortality in the world, and 
atherosclerosis is a hallmark in the 
disease. People with SLE have a 6-fold 
higher risk of developing atherosclerotic 
lesions that cause cardiovascular disease 
(Leng, Li, & ...Ye, 2015). “Increasing 
evidence shows that the cardiovascular 
morbidity and mortality are significantly 
higher in SLE than in the general 
population” (p.23).  
Just a couple of years back my 
mother had a Non ST Elevated 
Myocardial Infarction which lead to her 
diagnosis of SLE. Our family was not 
knowledgeable regarding this condition 
because no one in our family has SLE. 
Now every chance I get I try to learn as 
much about SLE to help better care for 
my mother and myself. Through research 
I’ve learned that I have a few of the risk 
factors that would put me at a higher 
incidence of developing the condition. 
Firstly,  I am an African American 
woman of childbearing age which 
increases my prevalence of developing 
the condition. This is an eye opener for 
because in SLE young women have a 50 
times higher risk for myocardial 
infarction compared to healthy women of 
similar age distribution (Giannelou & 
Mavragani, 2017).  Secondly, I have a 
higher incidence due to the fact that SLE 
is hereditary and my mom has the 
condition. It is for these reasons that I 
chose to research SLE. 
Signs & Symptoms
•Fatigue
•Fever
•Joint pain, stiffness and 
swelling
•Butterfly-shaped rash on face
•Photosensitivity
•Chest pain when taking a 
deep breath
•Hair loss
•Weight loss
•Mouth sores
•Raynaud’s phenomenom
•Swollen lymph nodes
•Headaches
•Memory loss
•Seizures
(Paz MD, 2017) 
Diagnosis
Lupus is difficult to diagnose 
because its signs and symptoms mimic 
other conditions. This is a condition that 
progresses slowly over years, and it has 
episodic periods of exacerbation and 
remission. (Paz MD, 2017). You have to 
have at least four of the eleven clinical 
findings to be diagnosed with SLE:
1.) Malar Rash
2.) Discoid Rash
3.) Mouth Ulcers
4.) Photosensitiviety
5.) Arthritis
6.) Lung or Heart Inflammation
7.) Renal Problems
8.) Neurologic Problems
9.) Hematologic Problems
10.) Immunologic Problems
11.) Positive Antinuclear Antibodies
(Paz MD, 2017)
The exact mechanisms that lead to increased risk for heart failure in SLE are not known, 
however data shows that aberrant host-immune response and chronic inflammation lead to 
accelerated atherosclerosis (Al-Kindi, Dhakal, Kim, & Oliveira, 2018). “In addition, SLE has 
direct cardiac, vascular, and other systemic manifestations that lead to increased risk of 
cardiovascular disease and heart failure” (p.188).
Endothelial Dysfunction
Endothelial dysfunction is one of the earliest signs of atherosclerosis, resulting in increased 
expression of adhesion molecules and impaired vasodilation. An imbalance between circulating 
apoptotic endothelial cells (ECs) indicate vascular damage and contribute to endothelial 
dysfunction. Also patients with SLE have increased concentrations of reactive oxygen species 
and decreased antioxidant defense mechanisms which provide a conducive environment for 
oxidation of lipoproteins and atherosclerosis (Bortoluzzi, et al., 2018, pp. 2-3). 
Monocytes and T-Cell Recruitment and Activation
Monocytes can migrate into the intima and differentiate into macrophages, which leads to a 
further transformation into foam cells that secrete proinflammatory cytokines (Bortoluzzi, et al., 
2018). 
T-cells, predominately CD4 cells, have an increased affinity to infiltrate newly formed 
atherosclerotic plaques (Bortoluzzi, et al., 2018).
Toll-Like Receptors 
Toll-like receptors (TLRs) are a class of pattern recognition receptors expressed on multiple 
cells involved in innate immunity. In SLE, people have a dysregulated activation of TLRs, 
resulting in upregulated production of autoantibodies and cytokines (Bortoluzzi, et al., 2018). 
This leads to the recruitment of activated inflammatory cells, self-perpetuating the process of 
inflammation and plaque formation (p.3).
Cytokines
Cytokines such as interferons alpha and gamma (INF) are involved in atherosclerosis and SLE. 
“IFN alpha serves as a proatherogenic mediator through repression of endothelial nitric oxide 
synthase-dependent pathways promoting the development of endothelial dysfunction and 
cardiovascular disease in SLE” (Bortoluzzi, et al., 2018, p. 3). 
IFN gamma participates in atherogenesis by stimulating ECs and macrophage activation, 
proinflammatory mediator production, adhesion-molecule expression, and by inhibiting smooth 
muscle cell proliferation and collagen production (Bortoluzzi, et al., 2018, p. 3). 
Other cytokines participate in the initiation and perpetuation of the atherosclerotic process by 
stimulating the activation of macrophages, inducing the secretion of matrix metalloproteinases, 
upregulating the expression of adhesion molecules on the ECs, increasing the concentration of 
chemotactic messengers, and affecting the proliferation of smooth muscle cells (Bortoluzzi, et 
al., 2018, p. 3).
Significance of 
Pathophysiology
Nursing 
Implications
Conclusions
SLE Manifestations increase the risk 
factors for Heart Failure
Myocardial Dysfunction: Left Ventricular 
Systolic Dysfunction or Diastolic 
Dysfunction
Left Ventricular Hypertrophy: Secondary 
to arterial HTN and correlation between 
SLE duration and left ventricular mass
Valvular Disease: is common in SLE 
however over heart failure due to valvular
involvement is rare
Conduction System Disease: SLE may 
manifest as arrhythmias such as atrial
fibrillation and complete heart block
Endocarditis: SLE predisposes people to 
infective and non-infective endocarditis
Myocarditis: can lead to conduction 
problems, dilated cardiomyopathy, and 
heart failure
Pericardititis: manifests as pleuritic
substernal pain and the most frequent 
cause of symptomatic cardiac disease in 
SLE
Anaphospholipid Syndrome: predisposes 
people to valvular disease, arterial and 
venous thrombosis, and pulmonary 
hypertension
(Al-Kindi, Dhakal, Kim, & Oliveira, 
2018)
Active SLE is no longer the major 
cause of death in the condition. Now 
mortality arises from conditions such as 
cardiovascular disease or renal failure 
complications. Obesity and hypertension 
are some of the known contributors of 
atherosclerosis. It is recommended that 
SLE patients with these conditions do 
things to try to reverse or control the 
condition. Bichele and Petri recommend 
a 500 calorie deficit from their diet as a 
well as two and a half hours of moderate 
intensity aerobic exercise weekly to 
decrease obesity (2014).  Also, 
“guidelines recommend a target blood 
pressure of less than 130/80 mmHg" 
(Bichile & Petri, 2014) to manage 
hypertension.
Advances in disease management 
have improved survival of SLE patients 
and shifted the focus to other outcome 
parameters such as measuring quality of 
life (Carnarius, Chehab, & Schneider, 
2014). Caregivers should be sensitive to 
the mental and physical attributes that 
come along with SLE. Fatigue, 
depression, and pain are common 
symptoms in SLE that lead to a 
decreased quality of life. 
Depression and anxiety in SLE increases 
the incidence of co-morbidities such as 
cardiovascular disease (Carnarius, 
Chehab, & Schneider, 2014).
The pain and discomfort of SLE can be 
physically and mentally debilitating.  
Encourage SLE patients to maintain 
activity when the symptoms are mild or 
in remission (Carnarius, Chehab, & 
Schneider, 2014). 
Caregivers should be educated on the 
medications to help treat SLE, and be 
ready to advocate on their behalf. 
Hydroxychloroquine is an antimalarial
with known benefits in treating SLE, 
however the percentage of people taking 
the medication remains low (Chalumeau, 
Dunogue, Guern, Imber, & Morel, 
2014). Hydroxychloroquine helps 
“reduce the high cardiovascular risk of 
SLE patients” (p. 168).
Systemic Lupus Erythematosus is a 
complex autoimmune inflammatory 
condition that increases the risk for 
atherosclerosis. Cardiovascular disease is the 
leading cause of death in the U.S. and 
atherosclerosis is the most common risk 
factor. SLE is non curable however advances 
in research has allowed people with the 
condition to live longer. More research is 
needed on the complex pathophysiology of 
the condition to better understand the disease 
process. 
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